|
1
|
Edwards HC and Crumpton MJ:
Ca(2+)-dependent phospholipid and arachidonic acid binding by the
placental annexins VI and IV. Eur J Biochem. 198:121–129.
1991.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liemann S and Lewit-Bentley A: Annexins: A
novel family of calcium- and membrane-binding proteins in search of
a function. Structure. 3:233–237. 1995.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pepinsky RB, Tizard R, Mattaliano RJ,
Sinclair LK, Miller GT, Browning JL, Chow EP, Burne C, Huang KS,
Pratt D, et al: Five distinct calcium and phospholipid binding
proteins share homology with lipocortin I. J Biol Chem.
263:10799–10811. 1988.PubMed/NCBI
|
|
4
|
Ernst JD, Hoye E, Blackwood RA and Jaye D:
Purification and characterization of an abundant cytosolic protein
from human neutrophils that promotes Ca2(+)-dependent aggregation
of isolated specific granules. J Clin Invest. 85:1065–1071.
1990.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mussunoor S and Murray GI: The role of
annexins in tumour development and progression. J Pathol.
216:131–140. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gerke V and Moss SE: Annexins: From
structure to function. Physiol Rev. 82:331–371. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hedhli N, Falcone DJ, Huang B,
Cesarman-Maus G, Kraemer R, Zhai H, Tsirka SE, Santambrogio L and
Hajjar KA: The annexin A2/S100A10 system in health and disease:
Emerging paradigms. J Biomed Biotechnol.
2012(406273)2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Weiss R, Bitton A, Ben Shimon M, Elhaik
Goldman S, Nahary L, Cooper I, Benhar I, Pick CG and Chapman J:
Annexin A2, autoimmunity, anxiety and depression. J Autoimmun.
73:92–99. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sohma H, Imai S, Takei N, Honda H,
Matsumoto K, Utsumi K, Matsuki K, Hashimoto E, Saito T and Kokai Y:
Evaluation of annexin A5 as a biomarker for Alzheimer's disease and
dementia with lewy bodies. Front Aging Neurosci.
5(15)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhou T, Li Y, Yang L, Tang T, Zhang L and
Shi J: Annexin A3 as a prognostic biomarker for breast cancer: A
retrospective study. Biomed Res Int. 2017(2603685)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zeng C, Ke Z, Song Y, Yao Y, Hu X, Zhang
M, Li H and Yin J: Annexin A3 is associated with a poor prognosis
in breast cancer and participates in the modulation of apoptosis in
vitro by affecting the Bcl-2/Bax balance. Exp Mol Pathol. 95:23–31.
2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zeidan B, Jackson TR, Larkin SE, Cutress
RI, Coulton GR, Ashton-Key M, Murray N, Packham G, Gorgoulis V,
Garbis SD and Townsend PA: Annexin A3 is a mammary marker and a
potential neoplastic breast cell therapeutic target. Oncotarget.
6:21421–21427. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kim JY, Jung EJ, Park HJ, Lee JH, Song EJ,
Kwag SJ, Park JH, Park T, Jeong SH, Jeong CY, et al:
Tumor-suppressing effect of silencing of annexin A3 expression in
breast cancer. Clin Breast Cancer. 18:e713–e719. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhou T, Li Y, Yang L, Liu L, Ju Y and Li
C: Silencing of ANXA3 expression by RNA interference inhibits the
proliferation and invasion of breast cancer cells. Oncol Rep.
37:388–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhou T, Liu S, Yang L, Ju Y and Li C: The
expression of ANXA3 and its relationship with the occurrence and
development of breast cancer. J BUON. 23:713–719. 2018.PubMed/NCBI
|
|
16
|
Du R, Liu B, Zhou L, Wang D, He X, Xu X,
Zhang L, Niu C and Liu S: Downregulation of annexin A3 inhibits
tumor metastasis and decreases drug resistance in breast cancer.
Cell Death Dis. 9(126)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li J, Zhou T, Liu L, Ju YC, Chen YT, Tan
ZR and Wang J: The regulatory role of annexin 3 in a nude mouse
bearing a subcutaneous xenograft of MDA-MB-231 human breast
carcinoma. Pathol Res Pract. 214:1719–1725. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhu S, Li Y, Wang Y, Cao J, Li X, Wang J
and Wang X: Efficacy of neoadjuvant chemotherapy and annexin A3
expression in breast cancer. J BUON. 24:522–528. 2019.PubMed/NCBI
|
|
19
|
Liu C, Li N, Liu G and Feng X: Annexin A3
and cancer. Oncol Lett. 22(834)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xu R, Yin J, Zhang Y and Zhang S: Annexin
A3 depletion overcomes resistance to oxaliplatin in colorectal
cancer via the MAPK signaling pathway. J Cell Biochem.
120:14585–14593. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yang L, Men WL, Yan KM, Tie J, Nie YZ and
Xiao HJ: MiR-340-5p is a potential prognostic indicator of
colorectal cancer and modulates ANXA3. Eur Rev Med Pharmacol Sci.
22:4837–4845. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bai Z, Wang J, Wang T, Li Y, Zhao X, Wu G,
Yang Y, Deng W and Zhang Z: The MiR-495/annexin A3/P53 axis
ınhibits the ınvasion and EMT of colorectal cancer cells. Cell
Physiol Biochem. 44:1882–1895. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xie YQ, Fu D, He ZH and Tan QD: Prognostic
value of annexin A3 in human colorectal cancer and its correlation
with hypoxia-inducible factor-1α. Oncol Lett. 6:1631–1635.
2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Köllermann J, Schlomm T, Bang H, Schwall
GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W,
Sauter G, et al: Expression and prognostic relevance of annexin A3
in prostate cancer. Eur Urol. 54:1314–1323. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hamelin-Peyron C, Vlaeminck-Guillem V,
Haïdous H, Schwall GP, Poznanović S, Gorius-Gallet E, Michel S,
Larue A, Guillotte M, Ruffion A, et al: Prostate cancer biomarker
annexin A3 detected in urines obtained following digital rectal
examination presents antigenic variability. Clin Biochem.
47:901–908. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schostak M, Schwall GP, Poznanović S,
Groebe K, Müller M, Messinger D, Miller K, Krause H, Pelzer A,
Horninger W, et al: Annexin A3 in urine: A highly specific
noninvasive marker for prostate cancer early detection. J Urol.
181:343–353. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Qu S, Li XY, Liang ZG, Li L, Huang ST, Li
JQ, Li DR and Zhu XD: Protein expression of nucleophosmin, annexin
A3 and nm23-H1 correlates with human nasopharyngeal carcinoma
radioresistance in vivo. Oncol Lett. 12:615–620.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wan X, Guo D, Zhu Q and Qu R: microRNA-382
suppresses the progression of pancreatic cancer through the
PI3K/Akt signaling pathway by inhibition of Anxa3. Am J Physiol
Gastrointest Liver Physiol. 319:G309–G322. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ma XL, Jiang M, Zhao Y, Wang BL, Shen MN,
Zhou Y, Zhang CY, Sun YF, Chen JW, Hu B, et al: Application of
serum annexin A3 in diagnosis, outcome prediction and therapeutic
response evaluation for patients with hepatocellular carcinoma. Ann
Surg Oncol. 25:1686–1694. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF,
Wang DD, Lv L, Jiang SS, Zheng HX and Xia JC: Annexin A3 promotes
tumorigenesis and resistance to chemotherapy in hepatocellular
carcinoma. Mol Carcinog. 54:598–607. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ,
Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, et al: Annexin A3 as a
potential target for immunotherapy of liver cancer stem-like cells.
Stem Cells. 33:354–366. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tong M, Che N, Zhou L, Luk ST, Kau PW,
Chai S, Ngan ES, Lo CM, Man K, Ding J, et al: Efficacy of annexin
A3 blockade in sensitizing hepatocellular carcinoma to sorafenib
and regorafenib. J Hepatol. 69:826–839. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhu Q, Pan QZ, Zhong AL, Hu H, Zhao JJ,
Tang Y, Hu WM, Li M, Weng DS, Chen MY, et al: Annexin A3
upregulates the infiltrated neutrophil-lymphocyte ratio to remodel
the immune microenvironment in hepatocellular carcinoma. Int
Immunopharmacol. 89(107139)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bombelli S, Torsello B, De Marco S,
Lucarelli G, Cifola I, Grasselli C, Strada G, Bovo G, Perego RA and
Bianchi C: 36-kDa annexin A3 isoform negatively modulates lipid
storage in clear cell renal cell carcinoma cells. Am J Pathol.
190:2317–2326. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jung EJ, Moon HG, Park ST, Cho BI, Lee SM,
Jeong CY, Ju YT, Jeong SH, Lee YJ, Choi SK, et al: Decreased
annexin A3 expression correlates with tumor progression in
papillary thyroid cancer. Proteomics Clin Appl. 4:528–537.
2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zeng X, Wang S, Gui P, Wu H and Li Z:
Expression and significance of annexin A3 in the osteosarcoma cell
lines HOS and U2OS. Mol Med Rep. 20:2583–2590. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang J, Jia X, Meng X, Li Y, Wu W, Zhang
X, Xu H and Cui J: Annexin A3 may play an important role in
ochratoxin-induced malignant transformation of human gastric
epithelium cells. Toxicol Lett. 313:150–158. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Takahashi H, Kaniwa N, Saito Y, Sai K,
Hamaguchi T, Shirao K, Shimada Y, Matsumura Y, Ohtsu A, Yoshino T,
et al: Construction of possible integrated predictive index based
on EGFR and ANXA3 polymorphisms for chemotherapy response in
fluoropyrimidine-treated Japanese gastric cancer patients using a
bioinformatic method. BMC Cancer. 15(718)2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhai JM, Sun SJ, Wang W and Zeng C:
Expression of annexin A3 in gastric cancer and its correlation with
proliferation and apoptosis. Asian Pac J Cancer Prev. 15:3001–3004.
2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yu SY, Li Y, Fan LQ, Zhao Q, Tan BB and
Liu Y: Impact of annexin A3 expression in gastric cancer cells.
Neoplasma. 61:257–264. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang K and Li J: Overexpression of ANXA3
is an independent prognostic indicator in gastric cancer and its
depletion suppresses cell proliferation and tumor growth.
Oncotarget. 7:86972–86984. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Jın YF, Huang YT and Chen PF: ANXA3
deletion inhibits the resistance of lung cancer cells to
oxaliplatin. Eur Rev Med Pharmacol Sci. 24:3741–3748.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liu YF, Liu QQ, Zhang YH and Qiu JH:
Annexin A3 knockdown suppresses lung adenocarcinoma. Anal Cell
Pathol (Amst). 2016(4131403)2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li
RL, Cao SS, Cui J, Wang L, Wu Y and Wen AD: Regulatory mechanisms
of annexin-induced chemotherapy resistance in cisplatin resistant
lung adenocarcinoma. Asian Pac J Cancer Prev. 15:3191–3194.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao
L, Meng Z, Wu X, Xu M and Xu K: Cancer-associated fibroblasts
contribute to cisplatin resistance by modulating ANXA3 in lung
cancer cells. Cancer Sci. 110:1609–1620. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF,
Li C, Li F, Chen YH, Yi H, Yao HX and Chen ZC: Quantitative
proteome analysis reveals annexin A3 as a novel biomarker in lung
adenocarcinoma. J Pathol. 217:54–64. 2009.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bianchi C, Bombelli S, Raimondo F,
Torsello B, Angeloni V, Ferrero S, Di Stefano V, Chinello C, Cifola
I, Invernizzi L, et al: Primary cell cultures from human renal
cortex and renal-cell carcinoma evidence a differential expression
of two spliced isoforms of annexin A3. Am J Pathol. 176:1660–1670.
2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Le Cabec V, Russo-Marie F and
Maridonneau-Parini I: Differential expression of two forms of
annexin 3 in human neutrophils and monocytes and along their
differentiation. Biochem Biophys Res Commun. 189:1471–1476.
1992.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Nishiura H, Yamanegi K, Kawabe M,
Kato-Kogoe N, Yamada N and Nakasho K: Annexin A3 plays a role in
cytoplasmic calcium oscillation by extracellular calcium in the
human promyelocytic leukemia HL-60 cells differentiated by
phorbol-12-myristate-13-acetate. Exp Mol Pathol. 97:241–246.
2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Junker H, Suofu Y, Venz S, Sascau M,
Herndon JG, Kessler C, Walther R and Popa-Wagner A: Proteomic
identification of an upregulated isoform of annexin A3 in the rat
brain following reversible cerebral ischemia. Glia. 55:1630–1637.
2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yang L, Lu P, Yang X, Li K and Qu S:
Annexin A3, a calcium-dependent phospholipid-binding protein:
Implication in cancer. Front Mol Biosci. 8(716415)2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Boye TL and Nylandsted J: Annexins in
plasma membrane repair. Biol Chem. 397:961–969. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Rescher U and Grewal T: Highlight:
Annexins in health and disease. Biol Chem. 397:947–948.
2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Purvis GSD, Solito E and Thiemermann C:
Annexin-A1: Therapeutic potential in microvascular disease. Front
Immunol. 10(938)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hofmann A, Raguénès-Nicol C, Favier-Perron
B, Mesonero J, Huber R, Russo-Marie F and Lewit-Bentley A: The
annexin A3-membrane interaction is modulated by an N-terminal
tryptophan. Biochemistry. 39:7712–7721. 2000.PubMed/NCBI View Article : Google Scholar
|
